D & A Research B.V.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
Research at D & A Research B.V. concentrates on advancing care for cardiovascular disease by testing novel therapies that aim to lower the risk of heart attacks, strokes, and heart failure. The work includes patients with high cardiovascular risk, established atherosclerotic disease, and those with concurrent kidney or inflammatory conditions.
- Heart failure with preserved ejection fraction
- Heart failure with reduced ejection fraction
- Acute myocardial infarction and secondary prevention
- Mixed dyslipidemia and LDL‑C reduction
- Lipoprotein(a) lowering strategies
- Chronic kidney disease with systemic inflammation
These studies reflect the site’s commitment to reducing major adverse cardiovascular events and improving long‑term outcomes for patients across the Netherlands.
Nutritional and Metabolic Diseases
At D & A Research B.V., investigators explore how metabolic health influences heart disease, focusing on type 2 diabetes, obesity, and related disorders. Trials evaluate the impact of new agents on blood sugar control, weight management, and cardiovascular risk reduction.
- Type 2 diabetes with hypertension
- Obesity‑related cardiovascular risk
- Metabolic syndrome and dyslipidemia
- Elevated lipoprotein(a) in metabolic disease
- Nutritional interventions for lipid management
The research aims to develop integrated treatments that address both metabolic and cardiovascular health, supporting patients in achieving better overall outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 26 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Amgen Inc.2active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG5trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in D & A Research B.V.
lock Showing 1 of 23 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | Amgen Inc. | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 26 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 3 | Unknown | 2021-11-26 | 2023-09-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.